SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as community members digest the company's latest earnings report, with considerable focus on iPhone sales and forward guidance. Discussions revolve around the implications of revenue from China and the potential impact of AI advancements. Bullish sentiment appears to be fueled by the company's forecast for the holiday quarter.

UP AND TO THE RIGHT

UPRIGHT CRYPTO is gaining attention for its constructive chart patterns, with many community members noting the potential for a breakout. Discussions highlight the steady accumulation and consistent higher lows, suggesting a solid foundation. The community buzz indicates growing confidence and anticipation for a significant move.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the OG meme, emphasizing the power of grassroots movements over KOL-backed projects. Discussions revolve around community growth, with members expressing strong conviction and calling for a return to the original meme culture. The focus is on building a strong, unified community that can drive the project forward.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending due to a TD Cowen analyst reiterating a Buy rating with a $10 price target, citing the company's sales trajectory and strategic initiatives despite Medicare Part D coverage challenges for Xphozah. The community is discussing the potential for significant IBSRELA growth and the possibility of strategic acquisitions or mergers, fueled by Ardelyx's strong cash position. Heightened risks around cash flow and commercialization hurdles are also being weighed against the company's potential.

DLH Holdings Corp. engages in the provision of technology enabled business process outsourcing program management solutions and public health research and analytics. Its services and solutions include Defense and Veteran Health Solutions, Human Services and Solutions, Public Health and Life Sciences, and Infinibyte Cloud. The company was founded in 1969 and is headquartered in Atlanta, GA.

DLH Holdings Corp

DLHC is trending due to a recently secured $90M contract with Veteran Affairs, sparking considerable excitement within the community. Discussions revolve around the company's low float, positive net income, and potential for substantial growth, with some anticipating a significant price surge. The contract win is seen as a major catalyst, reinforcing the company's growth prospects in the government services sector.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the community rallies around the tokenization of the legendary Satoshi Nakamoto, viewing it as the 'Bitcoin of memes' and a symbol of crypto culture. The community is anticipating increased visibility with upcoming events, including a feature on Mario Nawfal's Roundtable, driving excitement and discussion around its potential.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

MRNA is trending amid renewed buyout speculation, with chatter focusing on potential acquirers and valuation. The community is weighing the likelihood of a deal, considering the company's mRNA platform and pipeline, but some are skeptical. Potential infringement payouts are also being discussed as a factor in a buyout.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its technical setup and potential breakout, with many noting the building momentum. Bullish sentiment appears to be driven by accumulation patterns and anticipation of increased volume. Some users are also excited about a hackathon project being submitted.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending downwards following a disappointing earnings report and guidance cut, leading to a significant stock drop and multiple analyst downgrades. The community is actively debating whether the stock is oversold and presents a buying opportunity, or if deeper issues exist, including concerns about debt and previous management's performance. Some investors are pointing to large dark pool prints as a potential sign of institutional interest, while others fear further declines and are drawing comparisons to past corporate collapses.

Almonty Industries, Inc. engages in mining, processing and shipment of tungsten concentrates. Its projects include Los Santos, Valtreixal, Almonty Korea Tungsten, Almonty Korea Moly, and Panasquiera. The company was founded on September 28, 2009 and is headquartered in Toronto, Canada.

Almonty Industries Inc

Almonty Industries is trending amid discussions about rising tungsten prices and its potential role as a key tungsten supplier outside of China, especially for the U.S. defense sector. Community members are closely watching for production updates from the Sangdong Mine and speculating about potential government partnerships, driving interest in ALM as a strategic play in critical minerals.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Investors focused on Dexcom’s lower gross margin of 61.3%, down about 170 basis points year-over-year, despite record revenue and earnings.</li><li>The company said elevated scrap and freight costs would continue to pressure margins in the near term, even as efficiency improvements are underway.</li><li>Some retail traders viewed the decline as a buying opportunity, calling the after-hours drop “uncalled for.”&nbsp;</li></ul>Dexcom shares slid 13% in after-hours trading on Thursday, as investors looked past a record third-quarter (Q3) profit and focused instead on rising costs and a cautious outlook for next year.The glucose monitoring company reported $1.21 billion in revenue for Q3, up 22% year over year, driven by strong demand across the U.S. and international markets. Net income jumped to $242.5 million, or $0.61 per share, its highest ever.Dexcom also raised its full-year revenue forecast to $4.63-$4.65 billion, representing around 15% growth. However, the company’s upbeat sales&nbsp;weren’t enough to offset concerns about profitability, as it said gross margins will remain near 61%, down about 170 basis points year over year.<h2 class="st-heading-2">Margin Pressure And Outlook</h2>The company acknowledged that elevated scrap rates and freight costs continued to eat into profits. Management said the hit was “roughly half and half” between manufacturing waste and shipping expenses, though both are expected to ease gradually in the coming quarters.Looking ahead, Dexcom projected double-digit revenue growth in 2026, but slightly below Wall Street’s expectations. The forecast does not yet include potential benefits from broader insurance coverage for type 2 diabetes patients, which the company said could provide upside later on.Dexcom added that its new 15-day G7 sensor, currently rolling out to users, will have a limited impact this year but should meaningfully boost margins and growth in 2026 once it gains wider reimbursement.<h2 class="st-heading-2">Growth Drivers Remain Intact</h2>Despite the market reaction, Dexcom’s underlying growth story remains strong. The company continues to expand its reach in the type 2 diabetes market, now covering nearly 6 million non-insulin patients in the U.S.International revenue grew 22%, led by strong momentum in France and Canada following new reimbursement coverage. Its consumer-focused continuous glucose monitor, Stelo, topped $100 million in sales within its first year, with plans to launch in more markets in 2026. Dexcom ended the quarter with over $3.3 billion in cash.<h2 class="st-heading-2">Stocktwits Traders Stay Bullish Despite Selloff</h2>On Stocktwits, retail sentiment for Dexcom was ‘extremely bullish’ amid a 921% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:959/126;" src="https://news.stocktwits-cdn.com/dxcm_ss_jpg_7ecd09626d.webp" alt="dxcm ss.jpg" width="959" height="126"><figcaption>DXCM sentiment and message volume as of October 30 | Source: Stocktwits</figcaption></figure>One user said the market reaction reflected disappointment that the company’s longtime executive, now CEO, had signaled that Wall Street’s expectations for 2026 growth were too high, while also acknowledging a slowdown in new patient starts.<stembedurl>https://stocktwits.com/freddycan/message/634416837</stembedurl>Another user said they hoped analysts would issue more bullish reports and raise price targets, describing the selloff as “uncalled for.”<stembedurl>https://stocktwits.com/longshortequities/message/634409824</stembedurl>A third user took the opposite stance, calling the pullback a buying opportunity.<stembedurl>https://stocktwits.com/Okadarlan/message/634408938</stembedurl><a href="https://stocktwits.com/symbol/DXCM">Dexcom’s stock</a> has declined 12% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the DexCom logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Dexcom Stock Plunges 13% After-Hours As Q3 Margin Pressures Eclipse Record Profit — Retail Sees ‘Buy The Dip’ Setup

Investors focused on Dexcom’s lower gross margin of 61.3%, down about 170 basis points year-over-year, despite record revenue and earnings.

Equity

DexCom (DXCM) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates

DexCom (DXCM) delivered earnings and revenue surprises of +7.02% and +2.72%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209...

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (DexCom or the Company) (NASDAQ: DXCM) for violations of 10(b) and...

Insights Into DexCom (DXCM) Q3: Wall Street Projections for Key Metrics

Beyond analysts' top-and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, Oct. 28, 2025 NEW...

DCXM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc. Investors

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired DexCom, Inc. (DexCom or the Company) (NASDAQ:DXCM) securities during the...

Rosen Law Firm Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between...

<ul class="summary-bullets"><li>Short seller Hunterbrook flagged three new deaths linked to the Dexcom G7 reported in&nbsp;the FDA MAUDE database.</li><li>It stated that at least 13 G7 users have died since the device launched in 2023.&nbsp;</li><li>This is&nbsp;the second time the firm has published data around Dexcom, after first disclosing its short position in September.</li></ul>Dexcom (DXCM) shares slipped in midday trade on Tuesday after short seller Hunterbrook reported three additional deaths linked to the company’s G7 continuous glucose monitor.<a href="http://stocktwits.com/symbol/DXCM">DXCM’s stock</a> fell nearly 2%, with retail sentiment on Stocktwits around the company trending in ‘bearish’ territory over the past day.&nbsp; Hunterbrook first&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dexcom-stock-slumps-after-hunterbrook-media-investigation-raises-concerns-about-its-g7-device/chD3f5NR3Tm">disclosed</a> its short position in September, citing inaccurate G7 readings that allegedly sent patients to ICUs or&nbsp;led to worse outcomes.&nbsp;<h2 class="st-heading-2">FDA Data Shows Device Risks</h2>The short seller&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/dexcom2/">said</a> the new deaths were documented in the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, which tracks adverse events involving medical devices. It noted that while the reports do not necessarily prove the device caused the deaths, they help regulators and manufacturers flag potential risks.Hunterbook highlighted that one report described a 69-year-old man whose G7 sensor failed to provide readings, and a second involved a patient using the G7 with an automated insulin pump, whose inaccurate reading may have contributed to fatal ketoacidosis. The third report cited a woman who relied on the G7’s receiver alarms, which had been recalled days earlier for failing to sound properly.<h2 class="st-heading-2">Ongoing Scrutiny And Product Concerns</h2>The short seller stated that at least 13 G7 users have died since the device launched in 2023.&nbsp;It said that even the FDA issued a warning letter to Dexcom in March 2025 following a surprise inspection that revealed unauthorized design changes to a key component, which internal testing found inferior.&nbsp;Dexcom reportedly continued selling the device despite these findings. The short seller stated that the resulting controversy has triggered executive departures, insider selling, and patients returning to older G6 devices or switching to competitors, while ongoing lawsuits and regulatory scrutiny weigh on the company.DXCM’s stock has declined 11% this year and more than 8% since Hunterbrook first disclosed its short position.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-holds-near-114-k-ahead-of-fed-rate-decision-sol-xrp-edge-higher/cLGjgObR3H9">Bitcoin Holds Near $114K Ahead of Fed Rate Decision — SOL, XRP Edge Higher</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Dexcom Shares Slide After Short Seller Flags 3 Additional Deaths From G7 Devices

Short seller Hunterbrook stated that at least 13 G7 users have died since the device launched in 2023. 

$DXCM Q3 &#39;25 Earnings Results &amp; Recap

Dexcom reported Q3 2025 revenue of $1.21B versus estimates of $1.18B and EPS of $0.61 versus estimates of $0.57, while raising revenue guidance to $4.63B-$4.65B, but lowering gross margin guidance to approximately 61%.

Stocktwits

Dexcom Inc

 Q3 '25 Earnings Results & Recap

Dexcom reported Q3 2025 revenue of $1.21B versus estimates of $1.18B and EPS of $0.61 versus estimates of $0.57, while raising revenue guidance to $4.63B-$4.65B, but lowering gross margin guidance to approximately 61%.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Current Price	$59.14
Prev Close	$68.18
Open	$68.36
Dividend Yield	0.00%
50-Day Moving Average	$71.52
Beta	0.86
Avg. Volume	6.35M
PE Ratio	47.75

52-Week High	$93.25
52-Week Low	$57.52
Market Capitalization	$26.74B
EPS (Annual)	$1.42
Price to Book	10.40
Revenue Per Employee	$391,553.40
Enterprise Value/EBITDA	N/A

DXCM
Dexcom Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DXCM News

DXCMDexcom Inc